Literature DB >> 20124443

Why doesn't imatinib cure chronic myeloid leukemia?

Robert L Redner1.   

Abstract

Imatinib mesylate has transformed the treatment for chronic myeloid leukemia (CML). The vast majority of patients obtain hematologic remission, with a low probability of progression of disease. Yet imatinib rarely cures CML, and current recommendations dictate lifelong treatment with imatinib. In this review we analyze the biology behind the failure of imatinib to fully eradicate CML. We review evidence that indicates that the leukemic stem cell for CML is inherently resistant to imatinib, and that imatinib treatment itself may enhance this resistance.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20124443      PMCID： PMC3227943          DOI： 10.1634/theoncologist.2009-0297

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  39 in total

1.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

Authors:  Catriona H M Jamieson; Laurie E Ailles; Scott J Dylla; Manja Muijtjens; Carol Jones; James L Zehnder; Jason Gotlib; Kevin Li; Markus G Manz; Armand Keating; Charles L Sawyers; Irving L Weissman
Journal:  N Engl J Med       Date:  2004-08-12       Impact factor: 91.245

2.  Correlation between CXCR4 and homing or engraftment of acute myelogenous leukemia.

Authors:  Giuseppe Monaco; John W Belmont; Marina Konopleva; Michael Andreeff; Sigal Tavor; Isabelle Petit; Orit Kollet; Tsvee Lapidot
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

3.  Clonal origin of chronic myelocytic leukemia.

Authors:  R D Barr; P J Fialkow
Journal:  N Engl J Med       Date:  1973-08-09       Impact factor: 91.245

4.  Clonal origin of chronic myelocytic leukemia in man.

Authors:  P J Fialkow; S M Gartler; A Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  1967-10       Impact factor: 11.205

5.  Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.

Authors:  Hagop M Kantarjian; Jorge E Cortes; Susan O'Brien; Rajyalakshmi Luthra; Francis Giles; Srdan Verstovsek; Stefan Faderl; Deborah Thomas; Guillermo Garcia-Manero; Mary Beth Rios; Jianqin Shan; Dan Jones; Moshe Talpaz
Journal:  Blood       Date:  2004-06-15       Impact factor: 22.113

6.  Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity.

Authors:  Kristin J Hope; Liqing Jin; John E Dick
Journal:  Nat Immunol       Date:  2004-05-30       Impact factor: 25.606

7.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

8.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Authors:  Tim P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee L Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich
Journal:  N Engl J Med       Date:  2003-10-09       Impact factor: 91.245

9.  Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission.

Authors:  Michael J Mauro; Brian J Druker; Richard T Maziarz
Journal:  Leuk Res       Date:  2004-05       Impact factor: 3.156

10.  Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.

Authors:  Gianantonio Rosti; Giovanni Martinelli; Simona Bassi; Marilina Amabile; Elena Trabacchi; Barbara Giannini; Daniela Cilloni; Barbara Izzo; Antonio De Vivo; Nicoletta Testoni; Giovanna Rege Cambrin; Francesca Bonifazi; Simona Soverini; Simona Luatti; Enrico Gottardi; Daniele Alberti; Fabrizio Pane; Francesco Salvatore; Giuseppe Saglio; Michele Baccarani
Journal:  Blood       Date:  2003-11-26       Impact factor: 22.113
View more
  5 in total

Review 1.  The Search for Disease-Modifying Therapies in Pulmonary Hypertension.

Authors:  Chen-Shan Chen Woodcock; Stephen Y Chan
Journal:  J Cardiovasc Pharmacol Ther       Date:  2019-02-17       Impact factor: 2.457

2.  Further phenotypic characterization of the primitive lineage- CD34+CD38-CD90+CD45RA- hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia.

Authors:  D Wisniewski; M Affer; J Willshire; B Clarkson
Journal:  Blood Cancer J       Date:  2011-09-30       Impact factor: 11.037

3.  Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.

Authors:  Na Liu; Peng Li; Shaolei Zang; Qiang Liu; Daoxin Ma; Xiulian Sun; Chunyan Ji
Journal:  PLoS One       Date:  2015-02-03       Impact factor: 3.240

4.  Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia.

Authors:  Ilaria S Pagani; Orietta Spinelli; Elia Mattarucchi; Cristina Pirrone; Diana Pigni; Elisabetta Amelotti; Silvia Lilliu; Chiara Boroni; Tamara Intermesoli; Ursula Giussani; Luigi Caimi; Federica Bolda; Renata Baffelli; Eleonora Candi; Francesco Pasquali; Francesco Lo Curto; Arnalda Lanfranchi; Fulvio Porta; Alessandro Rambaldi; Giovanni Porta
Journal:  Oncoscience       Date:  2014-07-23

5.  FZD7 regulates BMSCs-mediated protection of CML cells.

Authors:  Na Liu; Shaolei Zang; Yan Liu; Yingqiao Wang; Wei Li; Qiang Liu; Min Ji; Daoxin Ma; Chunyan Ji
Journal:  Oncotarget       Date:  2016-02-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.